# A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy

Source: https://onco.cc/trials/nct05276310/  
OnCo record `nct05276310` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of IMC-002 run by ImmuneOncia Therapeutics Inc., now recruiting.

## Summary

A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy is a phase 1 interventional study registered as NCT05276310 by ImmuneOncia Therapeutics Inc., with 86 participants planned, started 2022-06-02. Conditions recorded: Advanced Cancer. Interventions recorded: IMC-002.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05276310
- Phase: 1
- Setting: An Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
- Sponsor: ImmuneOncia Therapeutics Inc.
- Enrolled: 86

## Sources

- ClinicalTrials.gov NCT05276310: https://clinicaltrials.gov/study/NCT05276310

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [IMC-002](https://onco.cc/drugs/imc-002/)
- companies: [ImmuneOncia Therapeutics](https://onco.cc/companies/immuneoncia-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct05276310.json